Compare AAT & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AAT | NBTX |
|---|---|---|
| Founded | 1967 | 2003 |
| Country | United States | France |
| Employees | 208 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | 2010 | 2018 |
| Metric | AAT | NBTX |
|---|---|---|
| Price | $23.61 | $35.15 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $19.50 | ★ $36.00 |
| AVG Volume (30 Days) | ★ 352.0K | 60.4K |
| Earning Date | 04-28-2026 | 03-31-2026 |
| Dividend Yield | ★ 6.65% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $436,204,000.00 | N/A |
| Revenue This Year | $4.33 | $58.17 |
| Revenue Next Year | $0.22 | N/A |
| P/E Ratio | $298.25 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $17.72 | $4.29 |
| 52 Week High | $23.97 | $57.14 |
| Indicator | AAT | NBTX |
|---|---|---|
| Relative Strength Index (RSI) | 74.07 | 40.76 |
| Support Level | $18.23 | $29.64 |
| Resistance Level | N/A | $41.89 |
| Average True Range (ATR) | 0.53 | 2.40 |
| MACD | 0.12 | -1.45 |
| Stochastic Oscillator | 87.95 | 2.24 |
American Assets Trust Inc is a self-administered real estate investment trust based in the United States. The company invests in, operates, and develops retail, office, residential, and mixed-use properties. Properties are predominantly located in South California, Northern California, Oregon, Washington, and Hawaii. American Assets operates through four segments based on property type: retail; office; mixed-use, which consists of retail and hotel components; and multifamily, which includes the company's apartment properties. The retail and office segments collectively contribute the majority of the total revenue.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.